PDF(Pubmed)
Abstract：
The increase in the number of patients with uncontrolled type 2 diabetes mellitus (T2DM) is in need of effective management interventions. However, research to date has been limited to the evaluation of the outcomes of community pharmacists alone. Therefore, the aim of the study protocol is to compare the effects of clinical pharmacist-led intervention strategies for the management of T2DM in the outpatient settings.
The study will collect and analyse data applying standard Cochrane methodological procedures. A search for eligible studies and ongoing trials will be conducted using PubMed, Embase, Medline (via Ovid), EBSCO (via Ovid), Lippincott Williams & Wilkins (LWW) Journals (via Ovid), ProQuest Health and Medical Complete, and ClinicalTrials.gov (clinicaltrials.gov) from database inception to December 2023. Clinical and health outcomes will be measured using both glycaemic control related indicators (eg, glycated haemoglobin, fasting blood glucose, postprandial glucose) and general indicators (eg, adherence, disease management and health-related quality of life). The meta-analysis will conduct pairwise meta-analysis using random effects models and network meta-analysis (NMA) employing the Bayesian hierarchical model. The visualisation and statistical analysis will be carried out using RevMan, R Studio and ADDIS. Additionally, we will evaluate the certainty of the evidence by using Grading of Recommendations Assessment, Development and Evaluation system.
There will be no primary data collection from NMA participants, and there is no requirement for formal ethical review. Our aim is to present the results of this NMA in a peer-reviewed scientific journal, at conferences, and in the mainstream media.
CRD42022355368.
The study will collect and analyse data applying standard Cochrane methodological procedures. A search for eligible studies and ongoing trials will be conducted using PubMed, Embase, Medline (via Ovid), EBSCO (via Ovid), Lippincott Williams & Wilkins (LWW) Journals (via Ovid), ProQuest Health and Medical Complete, and ClinicalTrials.gov (clinicaltrials.gov) from database inception to December 2023. Clinical and health outcomes will be measured using both glycaemic control related indicators (eg, glycated haemoglobin, fasting blood glucose, postprandial glucose) and general indicators (eg, adherence, disease management and health-related quality of life). The meta-analysis will conduct pairwise meta-analysis using random effects models and network meta-analysis (NMA) employing the Bayesian hierarchical model. The visualisation and statistical analysis will be carried out using RevMan, R Studio and ADDIS. Additionally, we will evaluate the certainty of the evidence by using Grading of Recommendations Assessment, Development and Evaluation system.
There will be no primary data collection from NMA participants, and there is no requirement for formal ethical review. Our aim is to present the results of this NMA in a peer-reviewed scientific journal, at conferences, and in the mainstream media.
CRD42022355368.
摘要：
背景：不受控制的2型糖尿病（T2DM）患者数量的增加需要有效的管理干预措施。然而,迄今为止的研究仅限于评估社区药剂师的结果。因此,本研究方案的目的是比较临床药师主导的干预策略在门诊2型糖尿病管理中的效果.
方法：本研究将使用标准Cochrane方法学程序收集和分析数据。搜索符合条件的研究和正在进行的试验将使用PubMed进行，Embase,Medline（通过Ovid），EBSCO（通过Ovid），LippincottWilliams&Wilkins(LWW)期刊(通过奥维德)，ProQuestHealthandMedicalComplete,和ClinicalTrials.gov（clinicaltrials.gov）从数据库开始到2023年12月。临床和健康结果将使用两种血糖控制相关指标进行测量（例如，糖化血红蛋白，空腹血糖,餐后葡萄糖)和一般指标(例如，坚持,疾病管理和与健康相关的生活质量)。荟萃分析将使用随机效应模型和采用贝叶斯分层模型的网络荟萃分析（NMA）进行成对荟萃分析。可视化和统计分析将使用RevMan进行，RStudio和ADDIS。此外,我们将通过使用建议评估等级来评估证据的确定性，开发和评估系统。
背景：将没有来自NMA参与者的主要数据收集，并且没有正式的道德审查要求。我们的目标是在同行评审的科学杂志上展示NMA的结果，在会议上,在主流媒体中。
■CRD42022355368。
方法：本研究将使用标准Cochrane方法学程序收集和分析数据。搜索符合条件的研究和正在进行的试验将使用PubMed进行，Embase,Medline（通过Ovid），EBSCO（通过Ovid），LippincottWilliams&Wilkins(LWW)期刊(通过奥维德)，ProQuestHealthandMedicalComplete,和ClinicalTrials.gov（clinicaltrials.gov）从数据库开始到2023年12月。临床和健康结果将使用两种血糖控制相关指标进行测量（例如，糖化血红蛋白，空腹血糖,餐后葡萄糖)和一般指标(例如，坚持,疾病管理和与健康相关的生活质量)。荟萃分析将使用随机效应模型和采用贝叶斯分层模型的网络荟萃分析（NMA）进行成对荟萃分析。可视化和统计分析将使用RevMan进行，RStudio和ADDIS。此外,我们将通过使用建议评估等级来评估证据的确定性，开发和评估系统。
背景：将没有来自NMA参与者的主要数据收集，并且没有正式的道德审查要求。我们的目标是在同行评审的科学杂志上展示NMA的结果，在会议上,在主流媒体中。
■CRD42022355368。
